Dr. Carrie L. Dul, MD

Dr. Dul practices at Henry Ford St. John Hospital in Detroit, Michigan, part of Henry Ford Health.

Dr. Dul's NPI, 1003820648, was assigned on July 28, 2006. Dr. Dul graduated from University of North Carolina at Chapel Hill School of Medicine in 1999. Dr. Dul holds Michigan license CD084925.

Dr. Dul's primary practice is Henry Ford St. John Hospital, at 22101 Moross Rd, Detroit, MI 48236 in Wayne County. The practice phone is (313) 343-4000.

Dr. Dul's primary practice is Henry Ford St. John Hospital in Detroit, Michigan, part of Henry Ford Health. Dr. Dul is also affiliated with Henry Ford Hospital. The medical group on file is Henry Ford St. John Hospital. Dmand AI also links Dr. Dul to 3 more hospitals, 2 group practices and clinics, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dul practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Dul's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Dul is licensed in Michigan.

CMS data shows 652 Medicare services from Dr. Dul across 8 procedure codes in 2024, for 365 Medicare patients. Medicare paid $40,278 for them.

CMS counts 365 Medicare patients who saw Dr. Dul in 2024. The largest group is 65 to 74, with 189 patients. 75% of them have cancer, and 70% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dul's median patient age at 69, with 91% women.

In 2024, Dr. Dul wrote 1,905 Medicare Part D claims for 417 patients. 85% of them were for generic drugs. CMS names the drug for 1,690 of them, across 22 drugs with 11 or more claims each, at $3,271,074 in total drug cost. In 2023, CMS named 1,599 claims across 17 drugs.

Dr. Dul accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 12 papers to Dr. Dul, published from 2016 to 2022. 2022 was the busiest year, with 4. The most frequent topics are Breast Neoplasms, Neoadjuvant Therapy and Antineoplastic Combined Chemotherapy Protocols. Dr. Dul has published most often in Ann Surg Oncol. Dr. Dul's most frequent co-authors are Laura Anne Lee, MD, James V. Pellicane, FACS, MD and Pat W. Whitworth, MD.

Dmand AI links Dr. Dul to 1 clinical trial. Conditions studied include Carcinoma, Ovarian Epithelial and Squamous Cell Carcinoma of Head and Neck.

CMS Open Payments shows 119 general payments to Dr. Dul from 35 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 49% of the total. Pfizer Inc. paid the most, $2,513. It also lists 3 research payments totaling $1,600 from 2021 to 2022.

Dr. Dul graduated from University of North Carolina at Chapel Hill School of Medicine in 1999.